Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-01
2005-11-01
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S363000
Reexamination Certificate
active
06960590
ABSTRACT:
The present invention relates to orally active salts of compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
REFERENCES:
patent: 5409930 (1995-04-01), Spada et al.
patent: 6656942 (2003-12-01), Fraley et al.
patent: WO 92/20642 (1992-11-01), None
patent: WO 97/06144 (1997-02-01), None
patent: WO 97/19927 (1997-06-01), None
patent: WO 97/44037 (1997-11-01), None
patent: WO 98/23613 (1998-06-01), None
patent: WO 00/09495 (2000-02-01), None
patent: 01/29025 (2001-04-01), None
Greenberg, Drug News Perspect, vol. 11, pp. 265-270 (1998).
Strawn et al. Exp. Opin. Invest. Drugs, vol. 7, pp. 553-573 (1998).
Dredge et al. Expert Opin. Biol. Ther. vol. 2, pp. 953-966 (2002).
Chinese Science Bulletin, vol. 36, No. 24, pp. 2056-2060 (1991), by J. Meng, et al.
Science in China, vol. 36, No. 5, pp. 540-549 (1993), by J. Meng, et al.
Oncogene, vol. 6, pp. 1677-1683 (1991), by B. Terman, et al.
J. Clin. Invest, vol. 104, No. 11, pp. 1613-1620 (1999), by N. van Bruggen, et al.
Drug News Perspect, vol. 11, No. 5, pp. 265-270 (1998), by D. Greenberg.
Nature, vol. 407, pp. 242-248 (2000), by G. Yancopoulos, et al.
Nature, vol. 407, pp. 249-257 (2000), by P. Carmeliet, et al.
J. Heterocyclic Chem., vol. 28, pp. 1481-1484 (1991), by J. Meng, et al.
Nature Biotech., vol. 17, pp. 963-968 (1999), by V. Brower.
Nature Medicine, vol. 5, No. 6, pp. 623-628 (1999), by H. Gerber, et al.
Molecular Cell, vol. 4, pp. 915-924 (1999), by B. Eliceirj, et al.
Stem Cells, vol. 12, pp. 1-6 (1994), by T. Burke, Jr.
Platelets, vol. 10, pp. 285-292 (1999), by A Amirkhosravi, et al.
FEBS Letters, vol. 473, pp. 161-164 (2000), by M. Nakagawa, et al.
Endocrinology, vol. 141, No. 5 pp. 1667-1674 (2000), by M. Deckers, et al.
Oncogene, vol. 5, pp. 519-524 (1990), by M. Shibuya, et al.
J. Med. Chem., vol. 37, pp. 2129-2137 (1994), by M. Maguire, et al.
J. Med. Chem., vol. 42, pp. 5369-5389 (1999), by L. Hennequin, et al.
Fraley Mark E.
Karki Shyam B.
Kim Yun-tae
Ayler Sylvia A.
Bernhardt Emily
Camara Valerie J.
Merck & Co. , Inc.
LandOfFree
Orally active salts with tyrosine kinase activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Orally active salts with tyrosine kinase activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally active salts with tyrosine kinase activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3494053